| Assessment Status | Rapid Review complete |
| HTA ID | 22049 |
| Drug | Capmatinib |
| Brand | Tabrecta® |
| Indication | Advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 11/07/2022 |
| Rapid review completed | 10/08/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of capmatinib compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.
